HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Abbisko Cayman - It Still Takes Some Time for Commercialization

Pre-IPO Beijing Airdoc Technology - The Strength and the Concerns

Pre-IPO Shanghai Ark Biopharmaceutical - Insights on Pipeline and Related Concerns

Chongqing Zhifei Biological Products (300122.CH) - Could Zhifei Support Its Valuation?

Industry Report - Insights on China Vaccine Industry

Pre-IPO YishengBio Co., Ltd  - Here Are the Concerns Despite Solid Market Potential

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Clover Biopharmaceuticals / Equity Capital Markets

<p>On April 23, 2021, <a href="https://www.smartkarma.com/entities/clover-biopharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:33029:1" rel="noopener">Clover Biopharmaceuticals (CBL HK)</a> filed a prospectus with the Hong Kong Stock Exchange in preparation for a listing in Hong Kong. Since the beginning of the 21st century, with the continuous emergence of innovative biotechnology enterprises in China, many research-based type of entrepreneurs have started their own businesses, such as Wang Xiaodong from <a href="https://www.smartkarma.com/entities/beigene-ltd" target="_blank" data-smartkarma-citation="entities:27352:1" rel="noopener">BeiGene Ltd (6160 HK)</a>, Yu Dechao from <a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics Inc (1801 HK)</a>, Du Ying from <a href="https://www.smartkarma.com/entities/zai-lab-ltd" target="_blank" data-smartkarma-citation="entities:25877:1" rel="noopener">Zai Lab Ltd (ZLAB US)</a>, etc. Liang Peng, the Founder of Clover Biopharmaceutical, also has an impressive background. He founded the Company in Chengdu in 2007 with his exclusive Trimer-Tag technology platform. The other core members of the Company include China's top pharmaceutical “think tank” such as Dr. Xiaodong Wang and Dr. Jianwei Zhu. So, are there any other highlights besides the outstanding team? This insight mainly analyzed the core technology platform and the core product candidates in the pipeline.</p>

On April 23, 2021, Clover Biopharmaceuticals (CBL HK) filed a prospectus with the Hong Kong Stock Exchange in preparation for a listing in Hong Kong. Since the beginning of the 21st century, with the continuous emergence of innovative biotechnology enterprises in China, many research-based type of entrepreneurs have started their own businesses, such as Wang Xiaodong from BeiGene Ltd (6160 HK), Yu Dechao from Innovent Biologics Inc (1801 HK), Du Ying from Zai Lab Ltd (ZLAB US), etc. Liang Peng, the Founder of Clover Biopharmaceutical, also has an impressive background. He founded the Company in Chengdu in 2007 with his exclusive Trimer-Tag technology platform. The other core members of the Company include China's top pharmaceutical “think tank” such as Dr. Xiaodong Wang and Dr. Jianwei Zhu. So, are there any other highlights besides the outstanding team? This insight mainly analyzed the core technology platform and the core product candidates in the pipeline.

Chongqing Zhifei Biological Products (300122 CH)

Zhejiang Hisun Pharmaceutical Co, Ltd. (600267 CH)

Pre-IPO Clover Biopharmaceuticals - Insights on the Core Technology and Product Candidates